The global Non-Small Cell Lung Cancer Treatment (NSCLC) market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
We have surveyed the Non-Small Cell Lung Cancer Treatment (NSCLC) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Non-Small Cell Lung Cancer Treatment (NSCLC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Small Cell Lung Cancer Treatment (NSCLC). This report contains market size and forecasts of Non-Small Cell Lung Cancer Treatment (NSCLC) in global, including the following market information:
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market revenue, 2020-2025, 2026-2032, ($ millions)
Global top five Non-Small Cell Lung Cancer Treatment (NSCLC) companies in 2024 (%)
Total Market by Segment:
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market, by Type, 2020-2025, 2026-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market segment percentages, by Type, 2024 (%)
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
Others
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market, by Application, 2020-2025, 2026-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market segment percentages, by Application, 2024 (%)
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market, by region and country, 2020-2025, 2026-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Small Cell Lung Cancer Treatment (NSCLC) revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Non-Small Cell Lung Cancer Treatment (NSCLC) revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Astellas Pharma
AstraZeneca
Avid Bioservices Inc.
Bayer Healthcare
Biogen Inc.
Blueprint Medicines Corp
Eli Lilly and Company
Merck & co Inc.
Novartis
Pfizer Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Small Cell Lung Cancer Treatment (NSCLC), market overview.
Chapter 2: Global Non-Small Cell Lung Cancer Treatment (NSCLC) market size in revenue.
Chapter 3: Detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Small Cell Lung Cancer Treatment (NSCLC) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Overall Market Size
2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size: 2024 VS 2032
2.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, Prospects & Forecasts: 2020-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players in Global Market
3.2 Top Global Non-Small Cell Lung Cancer Treatment (NSCLC) Companies Ranked by Revenue
3.3 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Companies
3.4 Top 3 and Top 5 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies in Global Market, by Revenue in 2024
3.5 Global Companies Non-Small Cell Lung Cancer Treatment (NSCLC) Product Type
3.6 Tier 1, Tier 2, and Tier 3 Non-Small Cell Lung Cancer Treatment (NSCLC) Players in Global Market
3.6.1 List of Global Tier 1 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Markets, 2024 & 2032
4.1.2 Angiogenesis Inhibitor
4.1.3 Epidermal Growth Factor Receptor Blocker
4.1.4 Kinase Inhibitor
4.1.5 Microtubule Stabilizer
4.1.6 Folate Antimetabolites
4.1.7 Others
4.2 Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue & Forecasts
4.2.1 Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2026-2032
4.2.3 Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2024 & 2032
5.1.2 Adenocarcinoma
5.1.3 Squamous Cell Carcinoma
5.1.4 Large Cell Carcinoma
5.2 Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue & Forecasts
5.2.1 Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2026-2032
5.2.3 Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
6 Sights by Region
6.1 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2024 & 2032
6.2 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue & Forecasts
6.2.1 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2025
6.2.2 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2026-2032
6.2.3 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
6.3 North America
6.3.1 By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2032
6.3.2 United States Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.3.3 Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.3.4 Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4 Europe
6.4.1 By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2032
6.4.2 Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4.3 France Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4.4 U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4.5 Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4.6 Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4.7 Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.4.8 Benelux Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.5 Asia
6.5.1 By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2032
6.5.2 China Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.5.3 Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.5.4 South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.5.5 Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.5.6 India Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.6 South America
6.6.1 By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2032
6.6.2 Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.6.3 Argentina Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2020-2032
6.7.2 Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.7.3 Israel Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.7.4 Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
6.7.5 UAE Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2020-2032
7 Companies Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Corporate Summary
7.1.2 AbbVie Inc. Business Overview
7.1.3 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.1.4 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.1.5 AbbVie Inc. Key News & Latest Developments
7.2 Astellas Pharma
7.2.1 Astellas Pharma Corporate Summary
7.2.2 Astellas Pharma Business Overview
7.2.3 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.2.4 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.2.5 Astellas Pharma Key News & Latest Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Corporate Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.3.4 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.3.5 AstraZeneca Key News & Latest Developments
7.4 Avid Bioservices Inc.
7.4.1 Avid Bioservices Inc. Corporate Summary
7.4.2 Avid Bioservices Inc. Business Overview
7.4.3 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.4.4 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.4.5 Avid Bioservices Inc. Key News & Latest Developments
7.5 Bayer Healthcare
7.5.1 Bayer Healthcare Corporate Summary
7.5.2 Bayer Healthcare Business Overview
7.5.3 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.5.4 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.5.5 Bayer Healthcare Key News & Latest Developments
7.6 Biogen Inc.
7.6.1 Biogen Inc. Corporate Summary
7.6.2 Biogen Inc. Business Overview
7.6.3 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.6.4 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.6.5 Biogen Inc. Key News & Latest Developments
7.7 Blueprint Medicines Corp
7.7.1 Blueprint Medicines Corp Corporate Summary
7.7.2 Blueprint Medicines Corp Business Overview
7.7.3 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.7.4 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.7.5 Blueprint Medicines Corp Key News & Latest Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Corporate Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.8.4 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.8.5 Eli Lilly and Company Key News & Latest Developments
7.9 Merck & co Inc.
7.9.1 Merck & co Inc. Corporate Summary
7.9.2 Merck & co Inc. Business Overview
7.9.3 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.9.4 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.9.5 Merck & co Inc. Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Corporate Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.10.4 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.10.5 Novartis Key News & Latest Developments
7.11 Pfizer Inc.
7.11.1 Pfizer Inc. Corporate Summary
7.11.2 Pfizer Inc. Business Overview
7.11.3 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.11.4 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2020-2025)
7.11.5 Pfizer Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Opportunities & Trends in Global Market
Table 2. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers in Global Market
Table 3. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints in Global Market
Table 4. Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC) in Global Market
Table 5. Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Share by Companies, 2020-2025
Table 8. Global Companies Non-Small Cell Lung Cancer Treatment (NSCLC) Product Type
Table 9. List of Global Tier 1 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type � Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2024 & 2032
Table 12. Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), 2026-2032
Table 14. Segmentation by Application� Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2024 & 2032
Table 15. Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 17. By Region� Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2024 & 2032
Table 18. By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 20. By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 22. By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 26. By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 28. By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2026-2032
Table 30. AbbVie Inc. Corporate Summary
Table 31. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 32. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 33. AbbVie Inc. Key News & Latest Developments
Table 34. Astellas Pharma Corporate Summary
Table 35. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 36. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 37. Astellas Pharma Key News & Latest Developments
Table 38. AstraZeneca Corporate Summary
Table 39. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 40. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 41. AstraZeneca Key News & Latest Developments
Table 42. Avid Bioservices Inc. Corporate Summary
Table 43. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 44. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 45. Avid Bioservices Inc. Key News & Latest Developments
Table 46. Bayer Healthcare Corporate Summary
Table 47. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 48. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 49. Bayer Healthcare Key News & Latest Developments
Table 50. Biogen Inc. Corporate Summary
Table 51. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 52. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 53. Biogen Inc. Key News & Latest Developments
Table 54. Blueprint Medicines Corp Corporate Summary
Table 55. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 56. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 57. Blueprint Medicines Corp Key News & Latest Developments
Table 58. Eli Lilly and Company Corporate Summary
Table 59. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 60. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 61. Eli Lilly and Company Key News & Latest Developments
Table 62. Merck & co Inc. Corporate Summary
Table 63. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 64. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 65. Merck & co Inc. Key News & Latest Developments
Table 66. Novartis Corporate Summary
Table 67. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 68. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 69. Novartis Key News & Latest Developments
Table 70. Pfizer Inc. Corporate Summary
Table 71. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 72. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn) & (2020-2025)
Table 73. Pfizer Inc. Key News & Latest Developments
List of Figures
Figure 1. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Picture
Figure 2. Non-Small Cell Lung Cancer Treatment (NSCLC) Segment by Type in 2024
Figure 3. Non-Small Cell Lung Cancer Treatment (NSCLC) Segment by Application in 2024
Figure 4. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue: 2020-2032 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2024
Figure 9. Segmentation by Type � Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2024 & 2032
Figure 10. Segmentation by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 11. Segmentation by Application � Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2024 & 2032
Figure 12. Segmentation by Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 13. By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 14. By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 15. United States Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 16. Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 17. Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 18. By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 19. Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 20. France Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 21. U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 22. Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 23. Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 24. Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 25. Benelux Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 26. By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 27. China Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 28. Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 29. South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 30. Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 31. India Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 32. By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 33. Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 34. Argentina Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 35. By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2020-2032
Figure 36. Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 37. Israel Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 38. Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 39. UAE Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2020-2032
Figure 40. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 50. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
